Tuesday, July 07, 2020 3:09:01 PM
$10 Stock potential. I still don't understand why this stock is so undervalued in phase 3 when the few other companies in or near phase 3 are in dollars? Maybe because there is so much more press on these Huge Corporations in or around phase 3? If FDA jumped it to phase 3 isn't it because they think it will more than likely pass 3?
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
